Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen

NCT01042925 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Breast Neoplasms

Interventions

DRUG: XL147 (SAR245408)
BIOLOGICAL: trastuzumab
DRUG: paclitaxel

Sponsor

Sanofi